Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Sep;34(3):215–223. doi: 10.1111/j.1365-2125.1992.tb04127.x

Postmarketing surveillance of captopril for hypertension.

D Chalmers 1, A Whitehead 1, D H Lawson 1
PMCID: PMC1381391  PMID: 1389946

Abstract

1. A scheme for augmented spontaneous reporting of adverse drug events using advanced view data systems was developed and applied to study 67,698 consecutive patients prescribed captopril in general practice for the treatment of hypertension. 2. Captopril was an effective hypotensive agent in this population, as only 1.9% of patients were withdrawn because of apparent inefficacy. 3. Adverse effects of captopril resulted in withdrawal of treatment in 8.9% of recipients, and such effects were more frequent in elderly and female recipients. 4. Skin reactions--usually maculopapular rashes--tended to occur early during therapy whereas cough occurred much later and was reported more frequently in non-smokers. 5. Some 1.1% of recipients died during follow-up. There was no evidence of any unusual or unexpected causes of death which might be partially or totally captopril-related in the study cohort. 6. The study confirms the feasibility of large scale postmarketing surveillance studied in general practice and allowed risk benefit assessments to be made on the use of captopril for treating hypertension.

Full text

PDF
215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chalmers D., Dombey S. L., Lawson D. H. Post marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol. 1987 Sep;24(3):343–349. doi: 10.1111/j.1365-2125.1987.tb03179.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colin Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med. 1985 Mar;54(215):253–268. [PubMed] [Google Scholar]
  3. Cooper W. D., Sheldon D., Brown D., Kimber G. R., Isitt V. L., Currie W. J. Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice. J R Coll Gen Pract. 1987 Aug;37(301):346–349. [PMC free article] [PubMed] [Google Scholar]
  4. Coulter D. M., Edwards I. R. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 1987 Jun 13;294(6586):1521–1523. doi: 10.1136/bmj.294.6586.1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  6. Edwards I. R., Coulter D. M., Beasley D. M., MacIntosh D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br J Clin Pharmacol. 1987 May;23(5):529–536. doi: 10.1111/j.1365-2125.1987.tb03088.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harcus A. W., Ward A. E., Smith D. W. Methodology of monitored release of a new preparation: buprenorphine. Br Med J. 1979 Jul 21;2(6183):163–165. doi: 10.1136/bmj.2.6183.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Maclay W. P., Crowder D., Spiro S., Turner P. Postmarketing surveillance: practical experience with ketotifen. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):911–914. doi: 10.1136/bmj.288.6421.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Yeo W. W., Maclean D., Richardson P. J., Ramsay L. E. Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double-blind conditions. Br J Clin Pharmacol. 1991 Mar;31(3):356–359. doi: 10.1111/j.1365-2125.1991.tb05544.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES